Unknown

Dataset Information

Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study.


ABSTRACT:

Background

Patients with CKD often have uncontrolled hypertension despite polypharmacy. Pharmacogenomic drug-gene interactions (DGIs) may affect the metabolism or efficacy of antihypertensive agents. We report changes in hypertension control after providing a panel of 11 pharmacogenomic predictors of antihypertensive response.

Methods

A prospective cohort with CKD and hypertension was followed to assess feasibility of pharmacogenomic testing implementation, self-reported provider utilization, and BP control. The analysis population included 382 subjects with hypertension who were genotyped for cross-sectional assessment of DGIs, and 335 subjects followed for 1 year to assess systolic BP (SBP) and diastolic BP (DBP).

Results

Most participants (58%) with uncontrolled hy

SUBMITTER: Eadon MT 

PROVIDER: S-EPMC8953763 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature